 Home > Active Ingredient News > Blood System > How should previously treated severe hemophilia A be treated?

How should previously treated severe hemophilia A be treated?

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

ln 0 1

main line waterproofing

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hemophilia is mostly a hereditary disease that prevents the body from clotting and forming a blood clot to stop bleeding
.

This causes the patient to bleed longer after injury, is prone to bruising, and increases the chance of hemorrhagic joints or bleeding in the brain

Pharmaceutical companies Sanofi and Sobi today announced that a Phase III study of efanesoctocog alpha in previously treated patients with severe hemophilia A met its primary endpoint, as well as a key secondary goal
.

The companies noted that data from the XTEND-1 trial will form the basis for regulatory submissions starting this year

The non-randomized study included 159 patients over 12 years of age with severe hemophilia A who had previously received factor VIII replacement therapy
.

The prophylaxis arm of the trial included subjects receiving efanesoctocog alpha at a dose of 50 IU/kg weekly for 52 weeks

prevention

First-line results showed clinically meaningful prevention of bleeding events in patients receiving weekly prophylaxis over 52 weeks, with an average annual bleeding rate (ABR) of 0.
71
.

First-line results showed clinically meaningful prevention of bleeding events in patients receiving weekly prophylaxis over 52 weeks, with an average annual bleeding rate (ABR) of 0.

"We believe that efanesoctocog alpha offers higher protection and longer duration," said Dietmar Berger, global head of development at Sanofi
.

Efanesoctocog alpha, also known as BIVV001, is an investigational recombinant factor VIII therapy designed to prolong bleeding protection in people with hemophilia A through once-weekly prophylactic dosing
.

Sobi decided to choose to develop the drug in 2019

Original source:

https://firstwordpharma.

https://firstwordpharma.
com/story/5521719 https://firstwordpharma.
com/story/5521719 Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.